All three branded drugs are now officially available in India. Select to compare.
Semaglutide 0.5mg / 1mg / 2mg
The original. Gold-standard GLP-1 for diabetes with proven cardiovascular benefits.
20+ brands from Natco, Sun Pharma, Glenmark, Dr Reddy's & more after patent expiry March 2026
Updated June 2026 — from NEJM, The Lancet, ASCO, and NIH
GLP-1 drugs reduce risk of heart attack and stroke by 14–20% in people with cardiovascular disease. The SELECT trial (Wegovy) showed 20% reduction in major cardiovascular events.
GLP-1 receptor agonists reduce albuminuria and risk of end-stage kidney disease. FLOW trial showed semaglutide reduced kidney failure risk by 24% in people with Type 2 diabetes and chronic kidney disease.
Multiple observational studies show GLP-1 users have significantly lower rates of alcohol use disorder, opioid overdose, and gambling disorder. GLP-1 receptors in the brain's reward circuit may reduce addictive cravings.
Early research suggests GLP-1 drugs may improve brain blood flow and reduce amyloid protein buildup associated with Alzheimer's. Clinical trials are underway. Results expected 2026–2028.
GLP-1 receptor agonists were associated with a modest but statistically significant reduction in hormone receptor-positive breast cancer incidence. ASCO 2026 research confirms the finding in non-diabetic women with BMI 25–35.
Semaglutide and tirzepatide both show significant improvement in NASH (Non-Alcoholic Steatohepatitis). ESSENCE trial showed semaglutide resolved NASH in 62% of patients vs 34% on placebo.
GLP-1 drugs reduce airway inflammation and oxidative stress, potentially benefiting patients with obesity-related asthma and sleep apnea. Studies show significant reduction in sleep apnea severity.
FDA black box warning: GLP-1 drugs caused medullary thyroid carcinoma in animal studies. Human evidence is mixed — no confirmed causal link in humans but the risk cannot be ruled out. Contraindicated in people with personal or family history of MTC.
Up to 25–40% of weight lost on GLP-1 drugs can be muscle mass, not fat. This is a concern especially for older adults. Resistance training and high protein intake (1.2–1.6g/kg) can significantly reduce muscle loss.
Systematic review shows patients regain 50–70% of lost weight within 1–2 years of stopping GLP-1 drugs. The drug does not cure obesity — it controls it. Lifelong use may be necessary for sustained benefit.
GLP-1 drugs may be associated with increased risk of osteoporosis, gout, and osteomalacia with long-term use, especially when significant muscle mass is lost. DEXA scan recommended for patients on long-term therapy.
Early concerns about acute pancreatitis have been largely dispelled by long-term clinical trials. The absolute risk increase, if any, is very small. Caution in patients with prior pancreatitis history.
The debates that matter. Balanced, evidence-based verdicts.
Quick eligibility check — not a substitute for medical advice